Halozyme Therapeutics Inc., founded in 1998 and headquartered in San Diego, California, develops and commercializes its proprietary ENHANZE enzyme technology to enable subcutaneous delivery of large molecule therapeutics. The company’s revenue is driven by royalties and milestone payments from partnerships with leading pharma companies. Led by CEO Paul Clancy since 2021, Halozyme is expanding its pipeline with new studies in oncology and immunology while strengthening its market position through strategic collaborations.